ALK-positive Non-Small Cell Lung Cancer Pipeline, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight's, "ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight, 2024," report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the ALK-positive Non-Small Cell Lung Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

* In October 2024:- Hoffmann-La Roche- The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
* In September 2024:- Pfizer- The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
* DelveInsight's ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 6+ active players working to develop 7+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment.
* The leading ALK-positive Non-Small Cell Lung Cancer Companies such as Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical , and others.
* Promising ALK-positive Non-Small Cell Lung Cancer Therapies such as Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s , and others.

Stay ahead with the most recent pipeline outlook for ALK-positive Non-Small Cell Lung Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ ALK-positive Non-Small Cell Lung Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile

* SY-3505: Shouyao Holdings

Ficonalkib (SY-3505) is a highly potent, adenosine triphosphate-competitive, CNS-penetrant, 3rd-gen ALK TKI. In vitro kinase assay revealed that ficonalkib exhibits potent inhibition against both wild-type ALK and a diverse spectrum of mutants observed in patients resistant to 1st- and 2nd-gen ALK TKI, including L1196M, G1202R, F1174L, G1269S, and R1275Q20. The drug exhibits high kinase selectivity and has very weak inhibition on tropomyosin receptor kinase (TRK). The drug is currently being evaluated under Phase III clinical trials for the treatment of NSCLC.

* APG-2449: Ascentage Pharma

APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development. The updated results at the ASCO indicated favorable safety and promising antitumor activity in patients with NSCLC, and the preliminary efficacy observed in patients who were resistant to second-generation ALK inhibitors was particularly encouraging. APG-2449 is currently being evaluated in Phase I clinical trial for Non-Small Cell Lung Cancer.

Explore groundbreaking therapies and clinical trials in the ALK-positive Non-Small Cell Lung Cancer Pipeline. Access DelveInsight's detailed report now! @ New ALK-positive Non-Small Cell Lung Cancer Drugs [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

ALK-positive Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Unveil the future of ALK-positive Non-Small Cell Lung Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* ALK-positive Non-Small Cell Lung Cancer Companies- Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.
* ALK-positive Non-Small Cell Lung Cancer Therapies- Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s, and others.
* ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on ALK-positive Non-Small Cell Lung Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ ALK-positive Non-Small Cell Lung Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* ALK Positive Non-Small Cell Lung Cancer : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* ALK Positive Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* SY-3505: Shouyao Holdings
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* APG-2449: Ascentage Pharma
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* ALK Positive Non-Small Cell Lung Cancer - Collaborations Assessment- Licensing / Partnering / Funding
* ALK Positive Non-Small Cell Lung Cancer - Unmet Needs
* ALK Positive Non-Small Cell Lung Cancer - Market Drivers and Barriers
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alkpositive-nonsmall-cell-lung-cancer-pipeline-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.